Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: An Australian and New Zealand experience

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 11, 2010, Pages 1732-1738

  Lawrance, Ian C ^a,b   Radford Smith, Graham L ^c,d   Bampton, Peter A ^f   Andrews, Jane M ^g   Tan, Pok Kern ^h   Croft, Anthony ^b   Gearry, Richard B ^h   Florin, Timothy H J ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e MATER HOSPITAL   (Australia)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Anti tumor necrosis factor alpha medication; Crohn's Disease; Infection; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; BACTEREMIA; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DIVERTICULOSIS; ENTERITIS; FEMALE; FEVER; FLU LIKE SYNDROME; HERPES ZOSTER; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION; INFECTION PREVENTION; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POSTOPERATIVE INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; STAPHYLOCOCCUS AUREUS; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS; UROSEPSIS;

EID: 78149246874     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06407.x     Document Type: Article

References (42)

1. Gearry RB, Richardson A, Frampton CMA et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm. Bowel. Dis. 2006; 12: 936-43.
2. Economics A. The economic costs of Crohn's Disease and ulcerative colitis. Australian Crohn's and Colitis Association 2007.
3. Rutgeerts P, Assche G, Vermeire S. Anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
4. Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
5. Hanauer S, Sandborn W, Rutgeerts P, Fedorak R. Human anti-tumour necrosis factor monoclonal antibody (Adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
6. Colombel J, Sandborn W, Rutgreerts P, Enns R. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM Trial. Gastroenterology 2007; 132: 52-65.
7. Trinder M, Lawrance I. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J. Gastroenterol. Hepatol. 2009; 24: 1252-7.
8. Pearce C, Lawrance I. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2007; 22: 1671-7.
9. Rutgeerts P, Feagan B, Olson A, Johanns J, Travers S, Present D. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005; 353: 2462-76.
10. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment. Pharmacol. Ther. 2009; 30: 126-37.
11. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
12. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48: 35-45.
13. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
14. Van Der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54: 2136-46.
15. Antoni C, Krueger GG, De Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 2005; 64: 1150-7.
16. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 3279-89.
17. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
18. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann. Rheum. Dis. 2007; 66: 163-8.
19. Willert R, Lawrance I. The use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J. Gastroenterol. 2008; 14: 2544-9.
20. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001; 345: 1098-104.
21. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. 2007; 52: 1481-4.
22. Shale M, Seow C, Coffin C, Kaplan G, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2009; 1: 20-34.
23. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk-a multicenter active-surveillance report. Arthritis Rheum. 2003; 48: 2122-7.
24. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50: 372-9.
25. Lawrance IC, Bampton PA, Sparrow M et al. Serious infective complications associated with anti-TNF alpha therapy in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2008; 23: A195.
26. Favalli EG, Desiati F, Atzeni F et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun. Rev. 2009; 8: 266-73.
27. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
28. Colombel JF, Loftus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
29. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-center cohort study. Gut 2009; 58: 501-8.
30. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. 2006; 4: 621-30.
31. Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005; 19: 5-36.
32. Lennard-Jones J. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. 1989; 170: 2-6.
33. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur. J. Clin. Microbiol. 2009; 28: 331-7.
34. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk-a multicenter active-surveillance report. Arthritis Rheum. 2003; 48: 2122-7.
35. Estrada S, Garcia-Campos F, Calderon R, Delgado E, Bengoa R, Enciso C. Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis. Inflamm. Bowel. Dis. 2009; 15: 315-16.
36. Roche P, Krause V, Konstantinos A et al. Tuberculosis notifications in Australia, 2006. Commun. Dis. Intell. 2008; 32: 1-11.
37. Das D, Baker M, Calde RL. Tuberculosis epidemiology in New Zealand: 1995-2004. N. Z. Med. J. 2006; 119: U2249.
38. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheumatic. Dis. 2008; 67: 189-94.
39. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNF alpha antagonists for chronic inflammatory joint disease. Joint. Bone Spine. 2008; 75: 540-3.
40. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-44.
41. Rahier JF, Ben-Horin S, Chowers T et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns. Colitis. 2009; 3: 47-91.
42. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia-associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006; 54: 628-34.